Science
PT-141 vs Melanotan II
Parent and derivative in the melanocortin family — what actually separates Melanotan II from PT-141 (bremelanotide) in structure, history, and research use.
PT-141 and Melanotan II are the most-confused pair in the melanocortin family — unsurprisingly, since one was derived from the other. The relationship is real, but so are the differences: in structure, in research focus, and in how far each travelled through formal development.
The short answer
Melanotan II is the parent: a cyclic α-MSH analog from the early 1990s, engineered for potency and stability, with broad melanocortin-receptor agonism and a literature dominated by melanogenesis. PT-141 (bremelanotide) is its derivative — a close structural relative whose research story shifted to the central MC3/MC4 receptor axis, and which went on through formal clinical development to regulatory approval as a medicine in one indication in 2019, a rarity in this family.
Side-by-side comparison
| Dimension | Melanotan II | PT-141 (bremelanotide) |
|---|---|---|
| Relationship | Parent compound | Derivative of Melanotan II |
| Structure | Cyclic α-MSH analog (lactam bridge) | Closely related cyclic analog |
| Receptor profile | Broad melanocortin agonist | Studied at the central MC3/MC4 axis |
| Research literature | Melanogenesis, pigmentation signalling, reference agonist | Central melanocortin pathways; formal clinical history |
| Development status | Research compound | Reached medicine approval in one indication (2019) |
| At REPRIME | Melanotan II 10 mg | PT-141 10 mg |
What they share
Both are cyclic peptides — the lactam-bridged architecture that solved native α-MSH's minutes-long survival — and both descend from the same 1990s engineering programme. As research materials they handle identically: lyophilized, stable, and verified the same way.
Where they differ
Emphasis. Melanotan II is the family's reference agonist: broad receptor engagement, with pigmentation research as its home turf and a standing role as the benchmark in melanocortin comparison tables — alongside the minimal fragment KPV at the other end of the family. PT-141's modification shifted its centre of gravity to central melanocortin signalling, and its passage through clinical development gives it something rare here: a formally documented regulatory history. For receptor-pharmacology work, the pair is valuable precisely because their differences map onto different receptor emphases within one structural family.
Frequently asked questions
Is PT-141 just Melanotan II under another name?
No — PT-141 is a distinct molecule derived from Melanotan II. They are close structural relatives with different research profiles and different development histories.
Which is the "reference" melanocortin agonist?
Melanotan II — its broad agonism and long literature make it the standard comparator, while PT-141 is the family's central-pathway specialist.
How are they supplied as research material?
Both ship from REPRIME as lyophilized 10 mg vials with batch HPLC verification, public COAs, and first-scan verification codes — see PT-141 and Melanotan II.